公开(公告)号：WO1986007387A1

公开(公告)日：1986-12-18

申请号：PCT/US1986001280

申请日：1986-06-13

Applicant: AMGEN ,  ABBOTT LABORATORIES

Inventor： AMGEN ,  ABBOTT LABORATORIES ,  SNITMAN, David, L. ,  STROUPE, Stephen, D.

IPC: C12Q01/68

CPC classification number: G01N33/54353 ,  C12Q1/6804 ,  C12Q1/6813 ,  C12Q1/705 ,  G01N33/532

Abstract: A method and a kit for the isolation and quantitative detection of a selected target nucleic acid sequence from solution employing two probes. A first probe is complementary to one portion of the target and is covalently attached to a first complexing agent (e.g., either an antigen or an antibody). The second probe is complementary to a different portion of the target and is associated with a reporter group. Following hybridization of the target and two probes in solution, a solid support coated with a second complexing agent (i.e., a corresponding antibody or antigen) capable of binding to the first complexing agent on the first probe is employed to immobilize the target-probe hybrid complex. A plurality of types of first probes may be used. Each type is attached to the same sort of complexing agent but each includes a nucleic acid sequence which is complementary to a different portion of the target.

Abstract translation: 用于使用两个探针从溶液中分离和定量检测所选靶核酸序列的方法和试剂盒。 第一个探针与靶的一部分互补，并且共价连接到第一络合剂（例如抗原或抗体）上。 第二个探针与目标的不同部分相互补充，并与报告者组相关联。 在溶液中杂交靶和两个探针之后，使用能够与第一探针上的第一络合剂结合的第二络合剂（即，相应的抗体或抗原）涂覆的固体支持物来固定靶 - 探针杂交体 复杂。 可以使用多种类型的第一探针。 每种类型都与相同种类的络合剂连接，但每种都包含与目标不同部分互补的核酸序列。

公开(公告)号：WO1985000829A1

公开(公告)日：1985-02-28

申请号：PCT/US1984001251

申请日：1984-08-09

Applicant: AMGEN

Inventor： AMGEN ,  MORRIS, Charles, F.

IPC: C12N15/00

CPC classification number: C12N15/69 ,  C07K14/485 ,  C07K14/56 ,  C07K14/65 ,  C12N15/73

Abstract: Novel circular DNA plasmids useful as vectors in recombinant methods to secure high levels of E. coli expression of exogenous genes. Plasmids of the invention comprise discrete DNA sequences operative to: (1) confer upon the plasmid the capacity for autonomous replication in a host cell; (2) control autonomous plasmid replication in relation to the temperature at which host cell cultures are maintained; (3) stabilize maintenance of the plasmid in host cell populations; (4) direct synthesis of a protein product indicative of plasmid maintenance in a host cell population; (5) provide, in series, a plurality of restriction endonuclease recognition sites, unique to the plasmid and facilitative of exogenous gene DNA sequence insertion; and (6) terminate mRNA transcription of adjacent DNA sequences and situated so as terminate transcription of exogenous gene sequences inserted within the plasmid at said unique restriction endonuclease restriction sites. Plasmids preferably have a size of less than 5.0 kilobases (exclusive of any inserted exogenous gene) and optionally include a DNA sequence operative to provide a strong promoter of mRNA transcription functionally associated with a temperature sensitive repressor sequence. A presently preferred embodiment of novel plasmids of the invention is plasmid pCFM414 (A.T.C.C. No. 40076).

公开(公告)号：WO1984003152A1

公开(公告)日：1984-08-16

申请号：PCT/US1984000151

申请日：1984-02-03

Applicant: AMGEN

Inventor： AMGEN ,  EGRIE, Joan

IPC: G01N33/54

CPC classification number: C07K16/22 ,  G01N33/746 ,  Y10S435/803 ,  Y10S435/948 ,  Y10S436/817 ,  Y10S436/824 ,  Y10S530/808 ,  Y10S530/809

Abstract: A new mouse-mouse hybridoma tumor cell line A.T.C.C. No HB8209. A monoclonal antibody produced by said cell line is specifically immunologically reactive with erythropoietin and with a polypeptide whose amino acid sequence is substantially duplicative of a sequence extant in erythropoietin. Disclosed also are procedures for isolation of erythropoietin by affinity purification and for quantitative detection of erythropoietin in fluid samples.

公开(公告)号：WO1984001154A1

公开(公告)日：1984-03-29

申请号：PCT/US1983001387

申请日：1983-09-13

Applicant: AMGEN

Inventor： AMGEN ,  ENSLEY, Burt, D.

IPC: C07H21/04

CPC classification number: C12P7/24 ,  C12N15/52 ,  C12P7/00 ,  C12P7/22 ,  C12P7/42

Abstract: Novel DNA sequences susceptible to expression in a microorganism in the form of synthesis of one or more enzymes participative in the microbiological oxidative degradation of a selected aromatic hydrocarbon substrate to a selected oxidized compound which is an intermediate in a multiple enzyme-catalyzed degradative pathway for total mineralization of said substrate. The DNA sequences are characterized by being substantially free from operative association with DNA sequences susceptible to expression in the form of synthesis of one or more enzymes participative in oxidative degradation of said selected intermediate compound. Illustrative of the invention is a plasmid-borne DNA sequence of Pseudomonas putida origin which codes for expression, in a hast microorganism such as E. coli, of enzymes participative in the oxidative degradation of napthalene to salicylate. Cultured growth of stably transformed host cells in a medium including a naphthalene substrate results in quantitative naphthalene degradation and accumulation of isolatable quantities of, e.g. salicylate products.

Abstract translation: 以微生物表达的形式的新型DNA序列，其以合成一种或多种酶的形式参与选择的芳族烃底物对选择的氧化化合物的微生物氧化降解，所述氧化化合物是多酶催化的降解途径中的中间体 所述基底的矿化。 DNA序列的特征在于基本上没有与以参与所述选择的中间体化合物的氧化降解的一种或多种酶的合成形式表达的DNA序列的有效结合。 本发明的说明书是恶臭假单胞菌（Pseudomonas putida）的质粒携带DNA序列，其编码在大肠杆菌等微生物中表达参与萘水杨酸氧化降解的酶。 在包含萘底物的培养基中培养的稳定转化的宿主细胞的生长导致定量的萘降解和可分离的量的积累。 水杨酸盐产品。

公开(公告)号：WO1987001391A1

公开(公告)日：1987-03-12

申请号：PCT/US1986001759

申请日：1986-08-26

Applicant: AMGEN

Inventor： AMGEN ,  FISHER, Eric, F.

IPC: C12P17/18

CPC classification number: C12N15/52 ,  C12P17/186

Abstract: A system for the production of biotin wherein a biotin retention-deficient strain of a cell is transformed with plasmid bearing the biotin gene cluster bio (A, B, F, C and D). The media of cultures of the resulting cells contains enhanced amounts of biotin by comparison with similar constructions in strains capable of biotin retention.

Abstract translation: 用生物素生物素（A，B，F，C和D）的质粒转化细胞生物素保留缺陷菌株的生物素生产系统。 通过与能够生物素保留的菌株中的类似结构相比，所得细胞的培养物培养基含有增加量的生物素。

公开(公告)号：WO1986007363A1

公开(公告)日：1986-12-18

申请号：PCT/US1986001290

申请日：1986-06-13

Applicant: AMGEN

Inventor： AMGEN ,  SNITMAN, David, L.

IPC: C07H15/12

CPC classification number: C07H21/00

Abstract: A composition and a method for 5'-labelling polynucleotides undergoing solid phase synthesis wherein a phosphoramidite of an upsilon-hydroxylamine is condensed to a support-bound polynucleotide.

公开(公告)号：WO1985002198A1

公开(公告)日：1985-05-23

申请号：PCT/US1984001747

申请日：1984-10-30

Applicant: AMGEN

Inventor： AMGEN ,  BANKS, Allen, R. ,  HARE, David, L.

IPC: C12P21/00

CPC classification number: C07K14/495 ,  C07K14/485 ,  C07K16/26 ,  C07K2319/036 ,  C07K2319/75 ,  C12N15/625

Abstract: Manufacture of DNA sequences comprising structural genes coding for (1) a polypeptide having the amino acid sequence and properties of Type I Transforming Growth Factor; (2) polypeptide analogs of Type I Transforming Growth Factor which differ from the naturally-occurring forms in terms of the identity and/or location of one or more amino acids, e.g., ADPhe15 BD rTGF, and ADAsp7 BD rTGF; and (3) hybrid polypeptides including, e.g., part or all of the Type I TGF amino acid residue sequence and part or all of the EGF amino acid residue sequence.

公开(公告)号：WO1987006940A1

公开(公告)日：1987-11-19

申请号：PCT/US1987001046

申请日：1987-05-05

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  AMGEN

Inventor： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  AMGEN ,  SLAMON, Dennis, J. ,  SOUZA, Lawrence, M.

IPC: C07K07/06

CPC classification number: C07K14/82 ,  A61K38/00 ,  C07K16/32 ,  G01N33/5748

Abstract: Methods and compositions for identifying patients suffering from cancer, particularly neural and neuroendocrine cancers. It has been found that the protein expression product of the human N-myc photo-oncogene may be detected in certain biological specimens, particularly tissue specimens and sputum samples. By obtaining immunogenic N-myc polypeptides, either synthetically or by isolation from a natural source, antibodies specific for the N-myc protein are obtained. Those antibodies may then be used in immunological techniques for detecting the presence of N-myc in the biological samples. In particular, the antibodies may be employed in immunohistochemical techniques to detect the N-myc protein in prepared tissue and sputum samples.

Abstract translation: 识别癌症患者的方法和组合物，特别是神经和神经内分泌癌症。 已经发现，人类N-myc光致癌基因的蛋白质表达产物可以在某些生物样品，特别是组织标本和痰样品中检测。 通过合成或通过从天然来源分离获得免疫原性N-myc多肽，获得对N-myc蛋白特异的抗体。 然后可以将这些抗体用于免疫学技术以检测生物样品中N-myc的存在。 特别地，抗体可用于免疫组织化学技术以检测制备的组织和痰样品中的N-myc蛋白。

公开(公告)号：WO1986006077A1

公开(公告)日：1986-10-23

申请号：PCT/US1986000680

申请日：1986-04-08

Applicant: AMGEN

Inventor： AMGEN ,  BITTER, Grant, A.

IPC: C07H21/04

CPC classification number: C07K14/005 ,  C07K14/57 ,  C12N15/81 ,  C12N2730/10122

Abstract: A hybrid promoter for controlling exogenous gene transcription is constructed by insertion of a UASG into a GPD portable promoter. The resulting hybrid promoter is placed upstream of an exogenous gene in a hybrid yeast-bacterial plasmid, which is used to transform yeast cells. Due to the regulation imparted to the GPD promoter by the UASG, transcription of the exogenous gene, and hence production of the exogenous gene product, may be regulated by controlling the composition of the carbon source in the yeast culture medium. Specifically, glucose is used to repress transcription and galactose is used to induce transcription.

Abstract translation: 通过将UASG插入GPD便携式启动子中构建用于控制外源基因转录的杂交启动子。 将所得杂交启动子置于杂交酵母 - 细菌质粒中的外源基因的上游，用于转化酵母细胞。 由于通过UASG赋予GPD启动子的调节，可以通过控制酵母培养基中碳源的组成来调节外源基因的转录，从而外源基因产物的产生。 具体来说，葡萄糖用于抑制转录，半乳糖用于诱导转录。

公开(公告)号：WO1985000817A1

公开(公告)日：1985-02-28

申请号：PCT/US1984001252

申请日：1984-08-09

Applicant: AMGEN

Inventor： AMGEN ,  SOUZA, Lawrence, M. ,  STABINSKY, Yitzhak

IPC: C07H21/04

CPC classification number: C12N15/69 ,  C07H21/04 ,  C07K14/55 ,  C12N15/70

Abstract: Manufacture of DNA sequences comprising structural genes coding for a polypeptide having the amino acid sequence and properties of Interleukin II and for polypeptide analogs of Interleukin II which differ from the naturally-occurring forms in terms of the identity and/or location of one or more amino acids, e.g., ADSer125 BDIL-II, ADGln26 BDIL-II, ADPhe121 BDIL-II, and ADStop121 BDIL-II.